title: Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor alpha.
authors.affiliation: Department of Rheumatology, University Hospital, Gent, Belgium. f.vandenbosch@pi.be
authors.forename: F
authors.initials: F
authors.lastname: Van den Bosch
authors.forename: D
authors.initials: D
authors.lastname: Baeten
authors.forename: E
authors.initials: E
authors.lastname: Kruithof
authors.forename: F
authors.initials: F
authors.lastname: De Keyser
authors.forename: H
authors.initials: H
authors.lastname: Mielants
authors.forename: E M
authors.initials: EM
authors.lastname: Veys
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D003141:Communicable Diseases / Q000276:immunology; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab; D009369:Neoplasms / Q000276:immunology; D010865:Pilot Projects; D016032:Randomized Controlled Trials as Topic; D025242:Spondylarthropathies / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab